About Santen Pharmaceutical Co., Ltd. (SNPHF) — Dividend Analysis 2026
Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase IIb clinical trial; DE-128 in Europe, as well as is in Phase II/III clinical trial in the United States; and DE-130A that is in Phase III clinical trial. In addition, the company provides DE-114A to treat allergic conjunctivitis; DE-076C for the treatment of vernal keratoconjunctivitis; and DE-109, which is in Phase III clinical trial to treat uveitis. Further, it offers DE-127 to treat myopia, which is in Phase II/III clinical trial in Japan, as well as is in Phase III in Asia; DE-089C, which has completed Phase III clinical trials for the treatment of dry eye; and STN1013400, which is in Phase I clinical trials for the treatment of myopia. Additionally, the company offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.
Is SNPHF a good dividend investment in 2026?
SNPHF offers a 2.31% forward yield with a 50% payout ratio. Strand Safety Score: 100/100 (Very Safe). The 5-year dividend CAGR of 33.6% demonstrates strong, consistent growth that outpaces inflation.
SNPHF DRIP calculator — what's the difference?
With DRIP on a $10,000 investment over 10 years, your SNPHF portfolio grows to $398.8K vs $353.8K without reinvestment. This is the compound interest effect in action.
SNPHF dividend growth history & forecast
SNPHF has grown its dividend by 0% over the last year and 33.6% annually over 5 years. At this pace, an investor who holds for 10+ years will see their yield on cost grow substantially above the current 2.31%.
Strand Safety Score™ is proprietary to DividendFlow. Inputs: FCF, Debt/EBITDA, Net Income from SEC filings via FMP. Not financial advice. N/A for ETFs, pre-revenue companies, and tickers without income statements.
🌍 SNPHF Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold SNPHF.
Gross yield
2.31%
Tax rate
15.00%
After-tax yield
1.96%
Real yield (−CPI)
-0.84%
Account/Country
Tax Rate
After-tax Yield
Real Yield
$10K Annual Income
🇺🇸 Roth IRA / 401k
0%
2.31%
-0.49%
$231 / yr
🇺🇸 US Taxable (15%) ✓
15%
1.96%
-0.84%
$196 / yr
🇺🇸 US Taxable (20%)
20%
1.85%
-0.95%
$185 / yr
🇬🇧 UK ISA
0%
2.31%
-0.49%
$231 / yr
🇬🇧 UK Taxable
8.75%
2.11%
-0.69%
$211 / yr
🇨🇦 TFSA
0%
2.31%
-0.49%
$231 / yr
🇨🇦 CA Taxable
25%
1.73%
-1.07%
$173 / yr
🇦🇺 Super (pension)
15%
1.96%
-0.84%
$196 / yr
🇦🇺 AU Taxable
30%
1.62%
-1.18%
$162 / yr
🇩🇪 DE Taxable
26.375%
1.70%
-1.10%
$170 / yr
🇫🇷 FR Taxable
30%
1.62%
-1.18%
$162 / yr
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 SNPHF Income Goal & Break-Even
Dividend Break-Even
10yr
Years for dividends to fully repay your SNPHF investment of $10.99/share (🇺🇸 US Taxable (15%) · 15.00% tax)
$10K invested · 10 Years
Dividends earned (DRIP)
$14.8K
Lost to inflation (2.8% CPI)
−$2.5K
Real purchasing power gain
$12.3K
12-month CPI (US BLS via FMP economic-indicators).
How much do I need to invest in SNPHF for:
Shares needed
111,238
Capital required
$1,222,506
Monthly income
$2,000
Based on current dividend of $0.25/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 SNPHF Dividend Payment Schedule
SNPHF pays quarterly — 4 times per year. Next ex-div: TBD.
Jan
Feb
Mar
💰
Apr
May
Jun
💰
Jul
Aug
Sep
💰
Oct
Nov
Dec
💰
10 shares
$0.54 / payment
$2.16 / year after tax
100 shares
$5.39 / payment
$21.58 / year after tax
1,000 shares
$53.94 / payment
$215.76 / year after tax
📊 SNPHF vs Healthcare Benchmarks
How SNPHF compares to typical Healthcare averages.
Benchmark: Healthcare
Dividend Yield▼-0.49% vs sectorBelow avg
SNPHF
2.31%
avg
2.80%
5Y Dividend CAGR▲+26.80% vs sectorBetter
SNPHF
33.60%
avg
6.80%
Payout Ratio▲-5.00% vs sectorBetter
SNPHF
50.00%
avg
55.00%
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for SNPHF sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ SNPHF Insider Activity
No recent SEC filings reported in the last 90 days.
📊 About This Data
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the SNPHF dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →